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ml of pre-hydrogel solution (poly(ethylene glycol) dimethacrylate
(10% w/v), photoinitiator (0.05% w/w) (Irgacure 2959) in phosphate
buffered saline) was exposured to 365 nm light (2 mW/cm2)
for 10 min solidifying the solution and encapsulating the cells
in gels of 5mm diameter and height. Inorganic pyrophosphate
(PPi) was added to the culture medium at 1mM. Control gels
did not receive PPi. Hydrogel properties were characterized by
compressive modulus, equilibrium swelling ratio (mass swollen
gel/mass of dry gel), and mesh size in the presence and absence
of PPi. Cell-laden constructs were cultured for 48 hours. Cell
viability was assessed using the LIVE/DEAD membrane integrity
assay after 48 hours. Cell proliferation was assessed by [3H]-
thymidine incorporation and proteoglycan synthesis by 35SO4-
incorporation. An n=3 was used for each condition. A student’s
t-test was performed with a p-value<0.05 considered signiﬁcant.
Results: The presence of PPi did not affect the macroscopic
properties of the hydrogel (Table 1). From the equilibrium swelling
ratio, which is a measure of the amount of water the hydrogel
imbibes, the mesh size was determined to between 18-20 nm
indicating that PPi can readily diffuse through the hydrogel.
Table 1. Macroscopic Properties of PEG Hydrogels in the Presence of PPi
Compressive Modulus Equilibrium Swelling Mesh Size
(kPa) Ratio (nm)
Control 110±17 12±2.2 18±4.4
PPi 110±6.0 13±2.0 20±4.1
The effects of PPi on cell proliferation and matrix production is
given in Table 2. PPi had no signiﬁcant effect on cell proliferation.
However, PPi dramatically inhibited proteoglycan synthesis by
72%. There was a 2.7-fold increase in proteoglycan loss into
the culture medium in the presence of PPi, which suggests that
proteoglycans are being degraded and which is mediated by PPi.
Table 2. Chondrocyte Response to PPi
Control PPi
Cell Proliferation (cpm/construct) 710±140 530±100
Proteoglycan Synthesis (cpm/construct) 7300±130 *2000±240
Percent Proteoglycan Loss (%/construct) 18±11 *49±3.7
*Denotes statistical signiﬁcance from control
Conclusions: High levels of exogenously delivered PPi to
chondrocyte-laden hydrogels inhibited matrix synthesis and in-
creased matrix loss into the culture medium, but did not affect
cell proliferation. Our ﬁndings suggest a role for PPi in mediating
matrix synthesis and degradation. PPi (at micromolar concentra-
tions) and PPi-derived Pi (at millimolar concentrations) are known
to be signaling molecules, and our results indicate that the ele-
vated (micromolar) level of extracellular PPi in aging cartilage, by
itself exerts functionally signiﬁcant effects on chondrocyte matrix
homeostasis.
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Purpose: Many people present themselves with hip or knee pain
at the general practitioners ofﬁce each year. The cause of this
pain is often thought to be osteoarthritis (OA), but not all these
people have radiological signs of OA in the painful joint.
It is not yet possible to determine in an early stage of the disease
who will develop OA pathology in a later stage. In this study
we aim to identify what the determinants are for developing OA
pathology on x-ray at follow-up, in people with pain at baseline but
no radiological OA (ROA) at baseline (Kellgren & Lawrence score
(K&L) ≤2).
Methods: Data of participants of the Rotterdam study (a
population-based cohort study), aged ≥55 years, was assessed
on the presence of hip or knee pain. A total of 452 subjects
with hip pain at baseline (mean age 68.5, 72.1% females) and
546 subjects with knee pain at baseline (mean age 70.0, 66.5%
females) were included; all without ROA in the painful joint at
baseline. Univariate and multivariate analyses (inclusion based on
p< 0.1 in univariate analyses) were used to determine predictors
for ROA at follow-up (mean 6.6 years). Tested baseline variables
include: other joint complaints and medical consumption for these
complaints, patient characteristics (age, sexe, diabetes), OA re-
lated aspects (familial OA, herberdens’ nodes, OA in other joint
(hip or knee) than the joint with complaints, morning stiffness, and
lower limb disability) and for women only female-hormone related
aspects (hormone use, age ﬁrst/last menstruation and years since
menopause).
Results: Of the included subjects with hip or knee pain at baseline
resp. 12.6% and 7.1% developed ROA at follow-up. Best predictor
of hip ROA at follow-up in those with hip pain was ‘knee OA
at baseline’ (K&L ≥2) in multivariate analysis of all subjects
(OR =4.362, p=0.016) as well as in univariat alnalysis in women
only (OR=4.700, p=0.036). For the men ‘familial OA’ (OR=6.114,
p=0.021) was the only signiﬁcant determinant in univariat analysis.
For predictors of knee ROA at follow-up in those with knee pain the
multivariate analysis of all subjects resulted in a model including
the determinants BMI (OR=1.305, p=0.016) and treatment of
joint complaints in the 5 years preceding baseline (OR=0.103,
p=0.044). In women the same variables remained signiﬁcant in
multivariate analysis with outcomes resp. OR=1.185, p=0.026 and
OR=0.288, p=0.029. For the men no variable was signiﬁcant
(p<0.05) in univariat analysis. All outcomes are adjusted for age.
Conclusions: Determining who will develop ROA in a later stage,
in people with joint pain but no radiographic OA, may help to
discriminate between true OA diagnosis and other pathologies.
It will also make it possible to identify subjects eligible for early
prevention studies, and with this hopefully preventing deterioration
into a severe OA in the future.
In predicting development of hip ROA, having knee OA and familial
OA seem to be the most important determinants. For development
of knee ROA best predictors are a combination of high BMI
and having had treatment for joint complaints in the ﬁve years
preceding baseline.
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Purpose: Pain is the most common, disabling symptom for people
with Osteoarthritis (OA). Improved understanding of pain mecha-
nisms in OA, including the development of "clinically feasible" tools
to identify individuals with central sensitization causing neuropathic
pain (NP) is essential to the development of mechanism-based
pain therapies. In adults with chronic symptomatic knee OA, this
study assessed: 1. the proportion of participants with NP symp-
toms as measured by a NP questionnaire modiﬁed for use in OA,
the modiﬁed painDETECT (mPD-Q); 2. convergent construct valid-
ity of the mPD-Q by co-administration of another NP questionnaire,
the Self-completed Leeds Assessment of Neuropathic Symptoms
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and Signs Pain Scale (S-LANSS); and, 3. factors associated with
NP symptoms as measured by the mPD-Q.
Methods: Eligible participants were members of an established
population-based OA cohort with chronic symptomatic knee OA.
A standardized questionnaire was mailed to 426 cohort members
to assess NP symptoms (mPD-Q, S-LANSS); osteoarthritis status
(WOMAC, Von Korff Chronic Pain Grade); psychological factors
including depression (Center for Epidemiological Studies Depres-
sion Scale), anxiety (Hospital Anxiety and Depression scale) pain
catastrophizing (Pain Catastrophizing Scale), and sleepiness (Ep-
worth Daytime Sleepiness scale); co-morbid medical conditions;
possible confounding neurological conditions; and medication use.
The cut-point score (≥19) identiﬁed in other chronic pain popu-
lations was used to identify NP symptoms (‘NP range’ scores) in
this study. The proportion of knee OA participants with mPD-Q
scores in the NP range was calculated using a 95% conﬁdence
interval (CI). Spearman’s correlation between continuous mPD-Q
and S-LANSS scores was examined. Potential correlates of NP
symptoms were ﬁrst assessed using bivariate analysis, followed
by logistic regression modeling.
Results: Out of 426 cohort members who were sent a study
questionnaire, 259 were deemed eligible to participate. The re-
sponse rate among eligible cohort members was 66% (171/259).
The proportion (95% CI) of participants with mPD-Q scores in
the NP range was 0.28 (0.21-0.35). After removal of participants
with neurological conditions, 0.19 (0.12-0.29) still had scores in
the NP range. Continuous mPD-Q scores were highly correlated
with continuous S-LANSS scores. NP range scores were strongly
associated with OA severity, depressive and anxious symptoms,
pain catastrophizing, and a higher frequency of neurological con-
ditions, and chronic back or hip pain with radiation down either
leg (‘pain radiation’). On multivariable analysis, pain intensity, ‘pain
radiation’, and neurological conditions were independently related
to NP range scores.
Conclusions: A substantial proportion of older adults with chronic
symptomatic knee OA had symptoms of NP on the mPD-Q sug-
gesting neuropathic mechanisms may be contributing to their pain
experience. This subgroup of people may beneﬁt from further
evaluation for NP and consideration of NP medications. Validation
work is ongoing on the mPD-Q, which may serve as a clinically
feasible tool to aid the identiﬁcation of NP in people with OA.
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Purpose: Selective activation of peripheral receptors has the im-
portant advantage of providing effective analgesia without side
effects typically associated with centrally acting drugs. Several
data suggest that both opioid and NMDA receptors are local-
ized at peripheral level, and drugs acting on these receptors may
produce antinociception after topical administration, however, the
antinociceptive effect of endogenous ligands at these receptors is
poorly clariﬁed. It is also well known that the organism can express
very effective antinociception in different circumstances by releas-
ing of various endogenous ligands. The goal of this study was to
determine the antinociceptive potency of the endogenous opioid
peptide, endomorphin-1, and the endogenous NMDA receptor an-
tagonist, kynurenic acid and their interaction at peripheral level in
the rat inﬂamed joint model.
Methods: Mechanical hypersensitivity was produced by injection
of carrageenan (300μg/20μl) into the tibiotarsal joint of the right
hind leg. The mechanical pain threshold, the withdrawal from me-
chanical stimulation to the plantar aspect of the hindpaws, was
assessed by logarithmic series of calibrated von Frey monoﬁl-
aments (0.064-110 g). Endomorphin-1 (30, 100 and 200 μg),
kynurenic acid (30, 100, 200 and 400 μg) and their combinations
in a ﬁxed-dose ratio: (1:1) were given into the inﬂamed joint 3
hours after the induction of inﬂammation, and the pain threshold
was determined repeatedly for 75 min after the drug administra-
tions. To determine the changes in the size of the inﬂamed joint,
the cross section area of ankle joint was also calculated.
Results: None of the treatments inﬂuenced the degree of edema.
Neither endomorphin-1 nor kynurenic acid administered to the
inﬂamed joint inﬂuenced the pain threshold at the non-inﬂamed
side. Both ligands produced dose-dependent anti-hyperalgesia,
and the highest doses caused prolonged effect. Endomorphin-
1 had higher potency (ED50 value was 112 μg [CI: 80-146])
compared to kynurenic acid (ED50 value was 204 μg [CI: 160-
251]). The coadministration of endomorphin-1 with kynurenic acid
caused potentiated and/or prolonged antinociceptive effect. The
ED50 value of the combination was 141 μg [CI: 83-182], which did
not differ signiﬁcantly from the theoretically additive value (ED50
145 μg [CI: 68-237]), thus the interaction between these ligands is
additive. None of the treatments caused any sign of side-effects.
Conclusions: This study has shown that the intra-articularly ad-
ministered endogenous μ-opioid receptor agonist EM1 and the
NMDA receptor antagonist KYNA dose-dependently decreased
the mechanical allodynia without signs of systemic side effects.
The coadministration of these ligands produced additive interac-
tion, thus a decreased dose of each drug can lead to effective
antinociception. Furthermore, we did not ﬁnd any changes on the
normal side. Therefore, we may exclude systemic antinocicep-
tive effects of these ligands. These results suggest an important
direction for the development of pain strategies that focus on
the coadministration of different endogenous ligands at peripheral
level.
This work was supported by a grant of the National Research
and Development Ofﬁce, Hungary (OMFB-0066/2005/DNT) and
the Hungarian Research Grant (OTKA, K60278).
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Purpose: To evaluate the construct validation of behavioural and
physiologic tools to measure orthopaedic pain induced in an ex-
perimental canine osteoarthritis (OA) model. We hypothesized
that these methods will present different validity and reliability be-
tween placebo-controlled and anti-resorptive (tiludronate)-treated
dogs. This drug was chosen for its potential as pain-killer without
sedative activity.
Methods: This prospective randomized blinded study was per-
formed on healthy adult dogs divided into two groups: Group 1,
eight control dogs, and Group 2, eight tiludronate-treated dogs,
2 mg/kg, subcutaneous. Under standardized procedures, transec-
tion of the right anterior cruciate ligament was carried out at Day
(D) 0. Treatments were repeated every two weeks from D0 to D56.
Two observers, blinded to treatment, assessed pain using the
visual analog scale (VAS) and multiparametric pain scale (Stan-
dardized Technician Arthritis Pain Scale [STAPS]/Observer 1 and
Standardized Veterinarian Arthritis Pain Scale [SVAPS]/Observer
2). Objective methods comprised podobarometric gait analysis
to record peak vertical force (PVF), locomotor activity record-
